AOD-9604: The HGH Fragment That Burns Fat Without the Side Effects

Here’s what the pharmaceutical companies don’t want widely known: the fat-burning effects of Human Growth Hormone are localized to a specific 16-amino-acid sequence at the C-terminus — fragment 176-191. Everything else in the full HGH molecule is responsible for the side effects: insulin resistance, water retention, IGF-1 elevation, carpal tunnel, potential tumor promotion. They’ve known this since the 1990s. AOD-9604 is that fragment — isolated, synthesized, and deployable without the baggage of full HGH.

AOD-9604 (Anti-Obesity Drug 9604) was originally developed by Metabolic Pharmaceuticals in Australia with the explicit goal of harnessing HGH’s fat-burning properties while eliminating its side effects. It reached Phase 3 clinical trials for obesity before development stalled due to funding — not safety concerns, not efficacy concerns. Funding.

How AOD-9604 Works

Lipolysis Stimulation

AOD-9604 activates lipolysis (the breakdown of stored fat into free fatty acids) via the same beta-3 adrenergic receptor pathway that full HGH uses for its fat-burning effects. It essentially mimics the fat-specific signaling of HGH without the downstream effects on IGF-1 pathways or insulin signaling.

Lipogenesis Inhibition

Beyond burning fat, AOD-9604 also inhibits lipogenesis — the process of converting carbohydrates and other substrates into new fat deposits. It’s working both sides of the equation: burning what’s there and preventing accumulation of new fat.

No IGF-1 Elevation

This is the key differentiator from full HGH. IGF-1 elevation is associated with accelerated cell growth (including potentially abnormal cells), insulin resistance, and water retention. AOD-9604 does not stimulate IGF-1 production or interact with growth hormone receptors in ways that trigger systemic growth effects. You get the fat loss. You don’t get the risks.

No Insulin Resistance

Full HGH at meaningful doses causes insulin resistance — it’s one of the primary reasons high-dose HGH users develop metabolic problems. AOD-9604 in clinical trials showed no effect on blood glucose or insulin sensitivity at doses up to 1 mg/day.

Clinical Trial Results

The Phase 2b clinical trial (n=300+) showed:

• Significant reduction in body fat vs. placebo at 12 weeks
• No effects on blood glucose, insulin, or IGF-1
• No significant adverse events vs. placebo
• Most pronounced effects in subjects with higher baseline body fat percentage

Notably, the fat loss occurred without dietary restriction in the trial — subjects were not placed on caloric deficits. The compound was working independently of diet.

AOD-9604 Protocol

This integrates into the Enhanced Athlete Protocol — Peptides and the Nutrition Protocol for body recomposition phases.

Fat Loss Protocol

• Dose: 250–300 mcg subcutaneous injection
• Timing: Upon waking, fasted (30–60 min before first meal)
• Frequency: Daily or 5 days on / 2 days off
• Duration: 12–20 week courses for meaningful results

Aggressive Recomp Protocol

• Dose: 500 mcg/day split into two injections (morning fasted + pre-bed)
• Stack: Combined with CJC-1295/Ipamorelin for morning dose timing overlap
• Duration: 16-week cycles

Optimal Stacking for Body Composition

AOD-9604 works best as part of a comprehensive approach from the Enhanced Athlete Protocol:

• AOD-9604 + CJC-1295/Ipamorelin: The growth hormone secretagogue stack amplifies overall GH pulsatility for muscle preservation and sleep quality; AOD-9604 handles targeted fat oxidation. This is a clean recomp protocol with no exogenous GH required.
• AOD-9604 + Tirzepatide/Semaglutide: GLP-1 receptor agonists suppress appetite and improve insulin sensitivity; AOD-9604 adds direct lipolytic action. Powerful combination for significant fat loss phases.
• AOD-9604 + BPC-157: If gut health and inflammation are compromised — BPC-157 heals the foundation while AOD-9604 runs the fat-burning protocol

Timing and Diet Optimization

AOD-9604’s lipolytic effects are enhanced in the fasted state — when insulin is low, free fatty acids can be mobilized more readily. Optimal approach:

• Inject AOD-9604 upon waking, before food or coffee
• Wait 30–60 minutes before first meal
• Lower carbohydrate intake on dosing days enhances effect
• Fasted morning cardio (20–30 min) post-injection dramatically amplifies fat oxidation

Bloodwork Monitoring

Per the Bloodwork Protocol:

• Fasting insulin and glucose: Baseline and 8 weeks in — confirm no metabolic impact
• IGF-1: Should remain unchanged; if elevated, reassess compound source
• Lipid panel: Track as adipose mobilization can temporarily shift lipid values
• DEXA scan: Most accurate fat mass measurement — baseline and at 12-week mark

Safety Profile

AOD-9604 is one of the safest fat loss peptides available based on clinical data. No carcinogenicity signals. No hormonal disruption. No insulin resistance. FDA GRAS (Generally Recognized As Safe) designation has been applied for based on its clinical trial data. The compound doesn’t suppress anything endogenous and doesn’t require PCT.

Compare this to stimulant-based fat burners that hammer your adrenals, or thermogenics that spike heart rate and blood pressure. AOD-9604 works through a hormonal mechanism that’s natural to the body — it’s mimicking what your own GH does for fat metabolism, just without the rest of GH’s effects.

For the complete body recomposition approach, see the full Enhanced Athlete Protocol and Training Protocol.